The Food and Drug Administration has licensed the first freeze-dried plasma product for use in the United States, opening a room-temperature option for adult patients who require plasma when conventional products are unavailable.
The product, Ezplaz Freeze Dried Plasma, is derived from a single unit of fresh frozen plasma collected by an FDA-licensed blood establishment. It is available as Group AB and as Group A with low-titer anti-B, blood-group configurations selected to reduce compatibility risk when a patient’s blood type is not yet known.
The license is narrower than a general replacement for hospital plasma. FDA says Ezplaz is indicated for adult transfusion when plasma is required and other plasma products are not available. The agency identified bleeding, massive transfusion and some bleeding patients taking warfarin as examples within that indication.
Conventional plasma must remain frozen and be thawed before use. Ezplaz can be stored at room temperature, remains stable after temperature fluctuations and can be rapidly reconstituted, according to FDA. Those features can reduce time and cold-chain demands in remote, disaster-response and other resource-limited settings.
Packaging also reflects those conditions. The freeze-dried unit is sealed in an outer foil pouch inside a plastic bag rather than a glass bottle. FDA said the plastic format reduces the chance of breakage during handling and transport.
Each self-contained kit includes one unit of freeze-dried plasma, a 250-milliliter bag of sterile water for injection, a sterile fluid-transfer set and a sterile blood-transfusion set. The components support preparation and administration without making the product a consumer or self-care treatment.
The approval does not eliminate transfusion risk. FDA said Ezplaz’s safety profile is consistent with other plasma products and advised health-care providers to review the full prescribing information. For the licensed uses, the agency concluded that the benefits outweigh the risks.
Freeze-dried plasma was an early focus of a Defense Department–FDA collaboration authorized in 2017 to speed work on products for serious or life-threatening conditions facing military personnel. FDA issued development guidance for dried plasma products in 2019.
The biologics license went to Vascular Solutions LLC, a subsidiary of Teleflex. The announcement did not provide a commercial rollout schedule, price or procurement volume, so the practical reach of the license will depend on manufacturing and adoption as well as the regulatory decision.
The immediate change is logistical and clinical: a licensed plasma product no longer has to arrive frozen, but it remains a regulated blood component for trained professionals, within a defined adult-use indication and with the established risks of transfusion.